Results from the phase 3 frontMIND trial demonstrated that tafasitamab plus lenalidomide and R-CHOP significantly improved PFS outcomes in previously untreated patients with high-risk diffuse large B-cell lymphoma or high-grade B-cell...
Results from the phase 3 frontMIND trial demonstrated that tafasitamab plus lenalidomide and R-CHOP significantly improved PFS outcomes in previously untreated patients with high-risk diffuse large B-cell lymphoma or high-grade B-cell...
Results from a phase 2 study demonstrated that replacing 2 intensive chemotherapy courses with blinatumomab improved outcomes and reduced treatment-related toxicity in newly diagnosed pediatric patients with high-risk B-cell acute...
Results from a phase 2 study demonstrated that replacing 2 intensive chemotherapy courses with blinatumomab improved outcomes and reduced treatment-related toxicity in newly diagnosed pediatric patients with high-risk B-cell acute...
Total marrow and lymphoid irradiation combined with high-dose etoposide and cyclophosphamide was feasible and associated with encouraging outcomes in patients with relapsed or refractory acute leukemia undergoing alloHCT, as demonstrated by...
Total marrow and lymphoid irradiation combined with high-dose etoposide and cyclophosphamide was feasible and associated with encouraging outcomes in patients with relapsed or refractory acute leukemia undergoing alloHCT, as demonstrated by...
Based on results from the phase 3 CAPItello-281 trial, the FDA has approved capivasertib plus abiraterone and prednisone for adult patients with metastatic androgen pathway modulation-naïve or -sensitive prostate cancer that is...
Based on results from the phase 3 CAPItello-281 trial, the FDA has approved capivasertib plus abiraterone and prednisone for adult patients with metastatic androgen pathway modulation-naïve or -sensitive prostate cancer that is...
Based on results from the phase 3 LITESPARK-022 trial, the FDA has approved adjuvant belzutifan plus pembrolizumab for adult patients with clear cell renal cell carcinoma at intermediate- or high risk of recurrence.
Based on results from the phase 3 LITESPARK-022 trial, the FDA has approved adjuvant belzutifan plus pembrolizumab for adult patients with clear cell renal cell carcinoma at intermediate- or high risk of recurrence.
Results from a phase 1 study demonstrated that PMB-CT01 shows encouraging activity in patients with relapsed or refractory B-cell non-Hodgkin lymphoma.
Results from a phase 1 study demonstrated that PMB-CT01 shows encouraging activity in patients with relapsed or refractory B-cell non-Hodgkin lymphoma.
The FDA has approved an orally disintegrating nilotinib formulation for adults with Ph–positive chronic myeloid leukemia that can be administered with acid-reducing agents and without food restrictions.
The FDA has approved an orally disintegrating nilotinib formulation for adults with Ph–positive chronic myeloid leukemia that can be administered with acid-reducing agents and without food restrictions.
Merck and Gilead have discontinued the phase 3 KEYNOTE-D46/EVOKE-03 trial after sacituzumab govitecan plus pembrolizumab failed to achieve a statistically significant PFS benefit in previously untreated metastatic NSCLC.
Merck and Gilead have discontinued the phase 3 KEYNOTE-D46/EVOKE-03 trial after sacituzumab govitecan plus pembrolizumab failed to achieve a statistically significant PFS benefit in previously untreated metastatic NSCLC.
Updated results from a phase 1a/1b study show that bexobrutideg continues to demonstrate strong clinical promise in chronic lymphocytic leukemia and small lymphocytic lymphoma.
Updated results from a phase 1a/1b study show that bexobrutideg continues to demonstrate strong clinical promise in chronic lymphocytic leukemia and small lymphocytic lymphoma.
Results from a phase 3 study demonstrated that the addition of polatuzumab vedotin to R-ICE did not improve outcomes in relapsed or refractory large B-cell lymphoma.
Results from a phase 3 study demonstrated that the addition of polatuzumab vedotin to R-ICE did not improve outcomes in relapsed or refractory large B-cell lymphoma.
